Cardarine (GW501516)

Cardarine (GW501516) is not a peptide but a synthetic peroxisome proliferator-activated receptor delta (PPARδ) agonist originally developed for metabolic and cardiovascular diseases. PPARδ activation increases fatty acid oxidation, improves lipid profiles, enhances endurance capacity, and promotes fat metabolism over glucose utilization. Research demonstrated dramatic increases in running endurance in animal studies without exercise training. The compound improves insulin sensitivity, raises HDL cholesterol, and lowers triglycerides. However, development was discontinued after long-term rodent studies showed increased cancer incidence in multiple organs. Despite these safety concerns, Cardarine remains popular in fitness communities for its perceived fat-burning and endurance-enhancing effects. The compound is banned by WADA for competitive athletes. Given the carcinogenicity signals in animal studies, Cardarine carries significant potential risks that have not been evaluated in long-term human trials. The compound is sometimes mistakenly grouped with SARMs despite having a completely different mechanism of action.

Cardarine is not a peptide and is not FDA approved. Clinical data are limited to one short human trial; the program was discontinued after rodent carcinogenicity findings, and no long-term human outcome or safety data exist. Any dosing advice circulating online has no clinical support.

Oral small-molecule PPARδ (PPARβ/δ) agonist; GW501516 activates PPARδ nuclear-receptor signaling to upregulate fatty-acid-oxidation genes. Human pharmacokinetic data are limited to short-term study protocols; it is not a peptide and has no approved dose.